Literature DB >> 18316422

A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.

Helen Blair Simpson1, Edna B Foa, Michael R Liebowitz, Deborah Roth Ledley, Jonathan D Huppert, Shawn Cahill, Donna Vermes, Andrew B Schmidt, Elizabeth Hembree, Martin Franklin, Raphael Campeas, Chang-Gyu Hahn, Eva Petkova.   

Abstract

OBJECTIVE: Although serotonin reuptake inhibitors (SRIs) are approved for the treatment of obsessive-compulsive disorder (OCD), most OCD patients who have received an adequate SRI trial continue to have clinically significant OCD symptoms. The purpose of this study was to examine the effects of augmenting SRIs with exposure and ritual prevention, an established cognitive-behavioral therapy (CBT) for OCD.
METHOD: A randomized, controlled trial was conducted at two academic outpatient clinics to compare the effects of augmenting SRIs with exposure and ritual prevention versus stress management training, another form of CBT. Participants were adult outpatients (N=108) with primary OCD and a Yale-Brown Obsessive Compulsive Scale total score > or = 16 despite a therapeutic SRI dose for at least 12 weeks prior to entry. Participants received 17 sessions of CBT (either exposure and ritual prevention or stress management training) twice a week while continuing SRI pharmacotherapy.
RESULTS: Exposure and ritual prevention was superior to stress management training in reducing OCD symptoms. At week 8, significantly more patients receiving exposure and ritual prevention than patients receiving stress management training had a decrease in symptom severity of at least 25% (based on Yale-Brown Obsessive Compulsive Scale scores) and achieved minimal symptoms (defined as a Yale-Brown Obsessive Compulsive Scale score < or = 12).
CONCLUSIONS: Augmentation of SRI pharmacotherapy with exposure and ritual prevention is an effective strategy for reducing OCD symptoms. However, 17 sessions were not sufficient to help most of these patients achieve minimal symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316422      PMCID: PMC3945728          DOI: 10.1176/appi.ajp.2007.07091440

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  42 in total

1.  Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?

Authors:  Herbert Y Meltzer
Journal:  Int J Neuropsychopharmacol       Date:  2005-03-21       Impact factor: 5.176

2.  The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD Family Study.

Authors:  G Nestadt; J Samuels; M A Riddle; K Y Liang; O J Bienvenu; R Hoehn-Saric; M Grados; B Cullen
Journal:  Psychol Med       Date:  2001-04       Impact factor: 7.723

3.  Determination of fluvoxamine in human plasma by high-performance liquid chromatography with ultraviolet detection.

Authors:  J P Foglia; L A Birder; J M Perel
Journal:  J Chromatogr       Date:  1989-10-27

4.  Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment.

Authors:  Nienke H Tenneij; Harold J G M van Megen; Damiaan A J P Denys; Herman G M Westenberg
Journal:  J Clin Psychiatry       Date:  2005-09       Impact factor: 4.384

5.  Response versus remission in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Jonathan D Huppert; Eva Petkova; Edna B Foa; Michael R Liebowitz
Journal:  J Clin Psychiatry       Date:  2006-02       Impact factor: 4.384

6.  Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder.

Authors:  T D Borkovec; E Costello
Journal:  J Consult Clin Psychol       Date:  1993-08

7.  Treatment of obsessive-compulsive disorder by U.S. psychiatrists.

Authors:  Carlos Blanco; Mark Olfson; Dan J Stein; Helen Blair Simpson; Marc J Gameroff; William H Narrow
Journal:  J Clin Psychiatry       Date:  2006-06       Impact factor: 4.384

8.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

9.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

10.  Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.

Authors:  Elizabeth A Hembree; David S Riggs; Michael J Kozak; Martin E Franklin; Edna B Foa
Journal:  CNS Spectr       Date:  2003-05       Impact factor: 3.790

View more
  61 in total

1.  Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.

Authors:  Martin E Franklin; Jeffrey Sapyta; Jennifer B Freeman; Muniya Khanna; Scott Compton; Daniel Almirall; Phoebe Moore; Molly Choate-Summers; Abbe Garcia; Aubrey L Edson; Edna B Foa; John S March
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

Review 2.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

3.  Understudied clinical dimensions in pediatric obsessive compulsive disorder.

Authors:  Adam B Lewin; Nicole Caporino; Tanya K Murphy; Gary R Geffken; Eric A Storch
Journal:  Child Psychiatry Hum Dev       Date:  2010-12

4.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

5.  A contemporary psychometric evaluation of the Obsessive Compulsive Inventory-Revised (OCI-R).

Authors:  Bethany M Wootton; Gretchen J Diefenbach; Laura B Bragdon; Gail Steketee; Randy O Frost; David F Tolin
Journal:  Psychol Assess       Date:  2015-02-09

6.  Intensive Family-Based Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder: Applications for Treatment of Medication Partial- or Nonresponders.

Authors:  Wendi E Marien; Eric A Storch; Gary R Geffken; Tanya K Murphy
Journal:  Cogn Behav Pract       Date:  2009-08

7.  What matters more? Common or specific factors in cognitive behavioral therapy for OCD: Therapeutic alliance and expectations as predictors of treatment outcome.

Authors:  Asher Y Strauss; Jonathan D Huppert; H Blair Simpson; Edna B Foa
Journal:  Behav Res Ther       Date:  2018-03-27

8.  Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.

Authors:  Michael G Wheaton; Marina Gershkovich; Thea Gallagher; Edna B Foa; H Blair Simpson
Journal:  Depress Anxiety       Date:  2018-02-02       Impact factor: 6.505

9.  Shared and Distinct Cognitive/Affective Mechanisms in Intrusive Cognition: An Examination of Worry and Obsessions.

Authors:  Richard J Macatee; Nicholas P Allan; Agnieszka Gajewska; Aaron M Norr; Amanda Medley Raines; Brian J Albanese; Joseph W Boffa; Norman B Schmidt; Jesse R Cougle
Journal:  Cognit Ther Res       Date:  2015-08-15

10.  Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.

Authors:  Carmen P McLean; Laurie J Zandberg; Page E Van Meter; Joseph K Carpenter; Helen Blair Simpson; Edna B Foa
Journal:  J Clin Psychiatry       Date:  2015-12       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.